Clinical trial
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid…
NCT00449761 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00449761 |
|---|---|
| Title | Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase |
| Official title | A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Chronic |
| Intervention type | Drug |
| Interventions | LBH589 |
| Enrollment | 27 |
| Start date | Feb 23, 2007 |
| Primary completion | Jan 29, 2008 |
| Completion | Aug 26, 2008 |
| First posted | Mar 21, 2007 |
| Last update posted | Jul 15, 2021 |
| Countries | Germany, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: